OverviewSuggest Edit

Fortress Biotech, Inc. is a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products. The Company develops and commercializes products both within Fortress and through certain of its subsidiary companies, also known as Fortress Companies. In addition to its internal development programs, Fortress leverages its biopharmaceutical business expertise and drug development capabilities. 

TypePublic
Founded2006
HQNew York, US
Websitefortressbiotech.com
Culture scoreC+

Latest Updates

Employees (est.) (Dec 2019)93(+6%)
Job Openings1
Revenue (FY, 2019)$36.6 M(+37%)
Share Price (May 2020)$3 (+7%)

Key People/Management at Fortress Biotech

Lindsay A. Rosenwald

Lindsay A. Rosenwald

Chairman, President and Chief Executive Officer
Michael S. Weiss

Michael S. Weiss

Executive Vice Chairman, Strategic Development
Eric K. Rowinsky

Eric K. Rowinsky

Co-Vice Chairman and Director
George Avgerinos

George Avgerinos

Senior Vice President, Biologics Operations
Jimmie Harvey

Jimmie Harvey

Director
Malcolm Hoenlein

Malcolm Hoenlein

Director
Show more

Fortress Biotech Office Locations

Fortress Biotech has offices in New York and Waltham
New York, US (HQ)
2 Gansevoort St
Waltham, US
95 Sawyer Rd #110
Show all (2)

Fortress Biotech Financials and Metrics

Fortress Biotech Revenue

Embed Graph
View revenue for all periods
Fortress Biotech's revenue was reported to be $36.63 m in FY, 2019 which is a 36.3% increase from the previous period.
USD

Revenue (Q1, 2020)

12.9m

Gross profit (Q1, 2020)

9.1m

Gross profit margin (Q1, 2020), %

70.5%

Net income (Q1, 2020)

(24.1m)

EBIT (Q1, 2020)

(21.5m)

Market capitalization (26-May-2020)

247.4m

Closing stock price (26-May-2020)

3.0

Cash (31-Mar-2020)

135.9m

EV

223.4m
Fortress Biotech's current market capitalization is $247.4 m.
Annual
USDFY, 2017FY, 2018FY, 2019

Revenue

187.6m26.9m36.6m

Revenue growth, %

(86%)36%

Cost of goods sold

3.7m6.1m10.5m

Gross profit

183.9m20.8m26.1m
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Revenue

44.7m50.7m46.9m55.4m63.8m63.7m6.5m9.3m9.8m12.9m

Cost of goods sold

469.0k878.0k505.0k1.5m1.7m1.9m2.4m2.7m3.8m

Gross profit

44.2m49.8m46.4m54.0m62.2m4.6m6.9m7.1m9.1m

Gross profit Margin, %

99%98%99%97%97%71%74%72%71%
Annual
USDFY, 2017FY, 2018FY, 2019

Cash

113.9m65.5m136.9m

Accounts Receivable

7.8m5.5m13.5m

Prepaid Expenses

12.7m6.7m4.1m

Inventories

171.0k678.0k857.0k
Quarterly
USDQ2, 2013Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Cash

67.9m134.0m144.3m110.5m124.0m98.6m95.9m116.4m149.4m134.9m135.9m

Accounts Receivable

1.4m3.3m5.6m8.3m5.3m5.4m8.0m3.1m5.1m15.8m

Prepaid Expenses

243.0k8.5m11.9m10.7m14.3m13.9m14.1m4.3m3.4m4.1m4.5m

Inventories

204.0k299.0k318.0k222.0k299.0k674.0k629.0k732.0k941.0k769.0k
Annual
USDFY, 2017FY, 2018FY, 2019

Net Income

(99.8m)(141.9m)(101.7m)

Depreciation and Amortization

2.8m1.4m1.9m

Inventories

32.0k(507.0k)(179.0k)

Accounts Payable

9.7m4.7m2.1m
USDY, 2020

EV/EBIT

-10.4 x

EV/CFO

-10.2 x

Financial Leverage

3 x
Show all financial metrics

Fortress Biotech Revenue Breakdown

Embed Graph

Fortress Biotech revenue breakdown by business segment: 18.7% from Other Branded, 76.6% from Targadox and 4.7% from Other

Fortress Biotech Online and Social Media Presence

Embed Graph

Fortress Biotech Company Culture

  • Overall Culture

    C+

    74/100

  • CEO Rating

    A+

    100/100

  • Compensation

    F

    43/100

Learn more on Comparably

Fortress Biotech News and Updates

Fortress Biotech Announces Rare Pediatric Disease Designation for CUTX-101 for the Treatment of Menkes Disease

Cyprium Therapeutics, a Fortress partner company, on track to begin submitting rolling New Drug Application for CUTX-101 to the FDA in the second half of 2020 Cyprium Therapeutics, a Fortress partner company, on track to begin submitting rolling New Drug Application for CUTX-101 to the FDA in the se…

Fortress Biotech Announces Exclusive Worldwide License Agreement With AstraZeneca and Cincinnati Children’s Hospital Medical Center to Develop a Novel Treatment for Select CNS Disorders

Baergic Bio, a Fortress partner company, enters into an agreement with AstraZeneca for AZD7325, a novel α2/3–subtype-selective GABA A positive allosteric modulator Baergic Bio, a Fortress partner company, enters into an agreement with AstraZeneca for AZD7325, a novel α2/3–subtype-selective GABA A po…

Fortress Biotech to Participate in December 2019 Investor Conferences

NEW YORK, Dec. 02, 2019 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on identifying, in-licensing and developing high-potential marketed and development-stage drugs and drug candidates, today announced that the company will…

Fortress Biotech Announces Pricing of Series A Preferred Stock Offering

NEW YORK, Nov. 25, 2019 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Common Stock: Nasdaq: FBIO) (Preferred Stock: Nasdaq: FBIOP) (“Fortress”), an innovative biopharmaceutical company focused on identifying, in-licensing and developing high-potential marketed and development-stage drugs and drug ca…

Fortress Biotech Ranked in Top 10 of Deloitte’s 2019 Technology Fast 500™

NEW YORK, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on identifying, in-licensing and developing high-potential marketed and development-stage drugs and drug candidates, today announced it ranked number 10 i…

Fortress Biotech Reports Third Quarter 2019 Financial Results and Recent Corporate Highlights

NEW YORK, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on identifying, in-licensing and developing high-potential marketed and development-stage drugs and drug candidates, today announced financial results and…
Show more

Fortress Biotech Blogs

Checkpoint Therapeutics Reports First Quarter 2020 Financial Results and Recent Corporate Highlights

NEW YORK, May 06, 2020 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers, today announ…

Avenue Therapeutics Announces Presentation of IV Tramadol E-Posters

NEW YORK, April 23, 2020 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announced that two e-posters highlighting efficacy and safety results from its Phase 3 program are availa…

Checkpoint Therapeutics Announces Issuance of U.S. Composition of Matter Patent for Anti-PD-L1 Antibody Cosibelimab

- U.S. patent protection through at least May 2038- Registration-enabling study of cosibelimab in cutaneous squamous cell carcinoma over one-third enrolled NEW YORK, April 21, 2020 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and…

Fortress Biotech Announces Up to $5 Million Series A Cumulative Redeemable Perpetual Preferred Stock Repurchase Program

NEW YORK, March 23, 2020 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or “the Company”), an innovative biopharmaceutical company focused on acquiring, developing and commercializing high-potential marketed pharmaceutical products and development-stage pharmaceutical produc…

Mustang Bio Reports Full-Year 2019 Financial Results and Recent Corporate Highlights

NEW YORK, March 16, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases…

Fortress Biotech Reports Record Fourth Quarter and Full-Year 2019 Financial Results and Recent Corporate Highlights

Revenue from marketed dermatology products increased 85% for fourth quarter 2019 and 49% for full-year 2019 compared to 2018 NDA for IV tramadol accepted for review by FDA; PDUFA date is set for October 10, 2020 Rolling NDA submission for CUTX-101 for the treatment of Menkes disease is on track …
Show more

Fortress Biotech Frequently Asked Questions

  • When was Fortress Biotech founded?

    Fortress Biotech was founded in 2006.

  • Who are Fortress Biotech key executives?

    Fortress Biotech's key executives are Lindsay A. Rosenwald, Michael S. Weiss and Eric K. Rowinsky.

  • How many employees does Fortress Biotech have?

    Fortress Biotech has 93 employees.

  • What is Fortress Biotech revenue?

    Latest Fortress Biotech annual revenue is $36.6 m.

  • What is Fortress Biotech revenue per employee?

    Latest Fortress Biotech revenue per employee is $393.9 k.

  • Who are Fortress Biotech competitors?

    Competitors of Fortress Biotech include MAX BioPharma, Lakewood-Amedex and Biophagy.

  • Where is Fortress Biotech headquarters?

    Fortress Biotech headquarters is located at 2 Gansevoort St, New York.

  • Where are Fortress Biotech offices?

    Fortress Biotech has offices in New York and Waltham.

  • How many offices does Fortress Biotech have?

    Fortress Biotech has 2 offices.